Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
Use of Additional Doses of 2024–2025 COVID-19 Vaccine in Adults Aged ≥65 Years and Persons Aged ≥6 Months With Moderate or Severe Immunocompromise
TAKE-HOME MESSAGE
- This report from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices summarizes the data and rationale behind the updated October 2024 recommendations. Based on the data indicating no residual effectiveness of prior monovalent vaccines and waning immunity over time, the Advisory Committee on Immunization Practices recommends that all persons aged 65 years and older as well as those aged between 6 months and 64 years with moderate or severely immunocompromising conditions receive a second dose of the 2024 to 2025 COVID-19 vaccine.
- Prior guidelines recommend vaccination for all individuals aged 6 months and older but do not elaborate on repeat dosing over the course of the year. This report also details how patients should engage in shared decision–making conversations with providers regarding additional doses depending on medical and vaccination history.
abstract
This abstract is available on the publisher's site.
Access this abstract nowCOVID-19 remains an important cause of morbidity and mortality, especially among adults aged ≥65 years and persons with moderate or severe immunocompromise; these persons are among those at highest risk for severe disease from COVID-19. On June 27, 2024, the Advisory Committee on Immunization Practices (ACIP) recommended 2024–2025 COVID-19 vaccination for all persons aged ≥6 months to target currently circulating strains of SARS-CoV-2 and provide additional protection against severe COVID-19. Because SARS-CoV-2 circulates year-round and immunity from vaccination wanes, on October 23, 2024, ACIP recommended a second 2024–2025 COVID-19 vaccine dose for all adults aged ≥65 years and for persons aged 6 months–64 years with moderate or severe immunocompromise, 6 months after their last dose of 2024–2025 COVID-19 vaccine (minimum interval = 2 months). Further, ACIP recommended that persons aged ≥6 months who are moderately or severely immunocompromised may receive additional doses of 2024–2025 COVID-19 vaccine (i.e., a total of ≥3 doses of 2024–2025 COVID-19 vaccine) based on shared clinical decision-making. Staying up to date with COVID-19 vaccination is recommended to decrease the risk for severe COVID-19, especially among adults aged ≥65 years and persons with moderate or severe immunocompromise.
Additional Info
Disclosure statements are available on the authors' profiles: